Pembrolizumab after kidney surgery for non-clear cell kidney cancer
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests whether the immunotherapy drug pembrolizumab can help prevent kidney cancer from coming back after surgery. It is for people with a less common type of kidney cancer called non-clear cell renal cell carcinoma that was at a higher stage or had spread but was fully removed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have had surgery to remove part or all of your kidney for a type of kidney cancer called non-clear cell renal cell carcinoma.
- Your cancer was at stage T3 or higher, or had spread to lymph nodes or other organs but was surgically removed.
- You have not received any prior cancer treatment for this kidney cancer other than surgery.
- You do not have an autoimmune disease that requires strong immune-suppressing medication.
- You are willing to use birth control if you or your partner could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing whether adding a gut health supplement (CBM588) to the immunotherapy drug pembrolizumab can help prevent kidney cancer from returning after surgery. It is for people with certain types of kidney cancer who have not had immunotherapy before.
This trial tests two immunotherapy drugs (botensilimab and balstilimab) given before surgery to remove a kidney tumor. The goal is to see if this approach is safe and helps shrink tumors in patients with advanced but non-spreading kidney cancer.
This trial is testing if adding the targeted therapy tivozanib to the immunotherapy drug pembrolizumab (Keytruda) can help prevent kidney cancer from coming back after all known tumors have been removed by surgery.
This trial tests two drugs, alone or together, given before surgery to shrink kidney cancer tumors. It aims to see which approach works best for patients with intermediate- to high-risk clear cell renal cell carcinoma.
This trial tests a combination of three medicines—pembrolizumab (a drug that helps your immune system fight cancer), belzutifan, and lenvatinib (drugs that slow tumor growth)—in patients with early-stage kidney cancer who are candidates for surgery. The goal is to see if this combination can improve outcomes before or alongside surgery.
This trial tests whether personalized monitoring of cancer DNA in your blood (MRD) can guide treatment decisions after kidney cancer surgery. If MRD is detected, you may receive extra immunotherapy to reduce the risk of cancer returning.
Hear when a new Stage III Renal Cell Cancer AJCC v8 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.